Follow-up and Outcomes of 186 Patients With Follicular Cell–Derived Thyroid Cancer Seen at a Referral Center by One Thyroidologist in 2015
Authors' conclusion
This report outlines the profile and outcomes of patients with FCDTC who were treated at a referral center before the revised 2016 American Thyroid Association guidelines. Lobectomy for low-risk FCDTC may miss some cancer in the contralateral lobe. However, the clinical importance of these missed microcarcinomas is unclear. Preoperative ultrasonography effectively predicts lateral, but not central compartment, nodal metastases.
Study context
- Population
- Patients with follicular cell-derived thyroid cancer (FCDTC) seen by one thyroidologist at Mayo Clinic in 2015, operated in 2015 or earlier; follow-up January 1, 2016, through July 20, 202285 total/near-total thyroidectomy
- Participants
- 186 patients
- Outcome
- Status at last follow-up
- Follow-up
- Last
Methodological detailssingle-centre, referral center, single thyroidologist
- Single-centre
- Referral center
- Single thyroidologist
Main finding
As reported in the abstract
No evidence of disease
65.6%
Distant metastases
10.7%
Observational data: associations, not effects.
Further findings
Bilateral disease in total or near-total thyroidectomy patients
- Bilateral disease
- 35.5%
- Contralateral involvement missed by lobectomy, low-risk thyroid cancer
- 9 (10%)
Neck lymph nodes · surgery
- Positive neck lymph nodes at surgery
- 57%
- Undetected by preoperative US
- 25%
- Undetected by preoperative US, central compartment
- 21%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →